To elucidate the mechanism(s) of cisplatin resistance, we have characterized a human non‐small cell lung cancer cell line (PC‐9/CDDP) selected from the wild type (PC‐9) for acquired resistance to cisplatin. PC‐9/CDDP demonstrated 28‐fold resistance to cisplatin, with cross resistance to other chemotherapeutic drugs including chlorambucil (× 6.3), melphalan (× 3.7) and 3‐[(4‐amino‐2‐methyl‐5‐pyrimidinyl)]methyl‐1‐(2‐chloroethyl)‐1‐nitrosourea (ACNU) (× 3.9). There was no expression of mdr‐1 mRNA in either wild‐type or resistant cells. The mRNA and protein levels of glutathione S‐transferase (GST) × were similar in the two lines. A GST‐μ isozyme was present in equal amounts and the activities of selenium‐dependent and independent glutathione peroxidase and glutathione reductase were unchanged. The mRNA level of human metallothionein IIA and the total intracellular metallothionein levels were reduced in the resistant cells. Significantly increased intracellular glutathione (GSH) levels were found in the resistant cells (20.0 vs. 63.5 nmol/mg protein) and manipulation of these levels with buthionine sulfoximine produced a partial sensitization to either cisplatin or chlorambucil. Increased GSH probably also played a role in determining cadmium chloride resistance of the PC‐9/CDDP, even though this cell line had a reduced metallothionein level. Also contributing to the cisplatin resistance phenotype was a reduced intracellular level of platinum in the PC‐9/CDDP. Thus, at least two distinct mechanisms have been selected in the resistant cells which confer the phenotype and allow degrees of cross resistance to other electrophilic drugs.
|Number of pages||9|
|Journal||Japanese Journal of Cancer Research|
|Publication status||Published - 1990 May|
- Cisplatin resistance
- Drug accumulation
ASJC Scopus subject areas
- Cancer Research